[Evaluation of the efficacy and safety of recombined human erythropoietin combined with cyclosporin A in the treatment of patients with pure red cell aplasia]

Zhonghua Xue Ye Xue Za Zhi. 2021 Nov 14;42(11):952-955. doi: 10.3760/cma.j.issn.0253-2727.2021.11.011.

[Article in Chinese]

Authors

Z S Chen¹, C Yang¹, M Chen¹, B Han¹

Affiliation

¹ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

PMID: 35045658
PMCID: PMC8763588
DOI: 10.3760/cma.j.issn.0253-2727.2021.11.011

No abstract available

MeSH terms

Cyclosporine
Erythropoietin*
Humans
Recombinant Proteins
Red-Cell Aplasia, Pure* / drug therapy

Substances

Recombinant Proteins
Erythropoietin
Cyclosporine

Grants and funding

基金项目：国家自然科学基金（81970106）；北京市自然科学基金（7192168）；中国医学科学院医学创新基金（2016-I2M-3-004）；中国医学科学院中央级公益性科研院所基本科研业务费专项（2019XK320047）